Ovarian cancer, Secondary cancers, Womb (uterine or endometrial) cancer
Results
Phase 2
This trial compared nintedanib to chemotherapy for women with clear cell cancer of the ovary or womb. It was for cancer that was getting worse or had come back after chemotherapy.
This trial was supported by Cancer Research UK.
It was open for people to join between 2015 and 2019. The team reported the results at a conference in 2020.
Recruitment start: 1 April 2015
Recruitment end: 25 July 2019
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Rosalind Glasspool
Boehringer Ingelheim
Cancer Research UK
European Organisation for Research and Treatment of Cancer
Experimental Cancer Medicine Centre (ECMC)
Group d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens
NHS Greater Glasgow and Clyde
NIHR Clinical Research Network: Cancer
Nordic Society of Gynaecological Oncology
Scottish Gynaecological Cancer Trials Group
This is Cancer Research UK trial number CRUKE/12/024.
Last reviewed: 2 July 2024
CRUK internal database number: 9542
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
